IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...

biote Corp. returned to profitability in Q3 2023 and is expected to continue to be profitable in the future. The company's growth is driven by the sale of hormone replacement therapy products and its ...

Investors who take an interest in biote Corp. (NASDAQ:BTMD) should definitely note that the Executive Chairman, Marc Beer, recently paid US$3.87 per share to buy US$417k worth of the stock. Although ...

IRVING, Texas - Biote Corp. (NASDAQ: BTMD), a preventive health care company specializing in personalized hormone optimization, has reached a settlement with its founder, Dr. Gary S. Donovitz, ...

I maintain my Strong Buy rating on biote Corp. due to its promising growth prospects, despite ongoing restructuring and short-term earnings pressure. The company’s vertical integration, digital ...

Biote Corp. ((BTMD)) has held its Q3 earnings call. Read on for the main highlights of the call. Biote Corp.’s latest earnings call revealed a mixed sentiment, with challenges and opportunities ...

This article first appeared on GuruFocus. Biote Corp (NASDAQ:BTMD) is set to release its Q3 2025 earnings on Nov 5, 2025. The consensus estimate for Q3 2025 revenue is $47.76 million, and the earnings ...

CEO Bret Christensen noted that "the second quarter was pivotal for Biote as we implemented a strategic organizational restructuring designed to drive increased and sustainable growth." He highlighted ...

IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...